long-term evaluation on height and weight in patients with mps ii who started treatment at < 6 years of age

Conditions: Hunter Syndrome

Summary: this long-term study will provide elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and hunter outcome survey (hos) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with mucopolysaccharidosis ii (hunter syndrome) mps ii.


Eligibility criteria:
inclusion criteria: * group 1: prospective patient group 1. the patient is male. 2. the patient is elaprase-naïve at study entry. 3. the patient must have a documented diagnosis of mps ii. of the 3 criteria below, the combinations (3a and 3b) or (3a and 3c) will be accepted as diagnostic of mps ii: 1. the patient has a deficiency in i2s enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range). and 2. the patient has a documented mutation in the i2s gene. or 3. the patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory). 4. the patient will be \<6 years of age at the start of elaprase treatment. 5. the patient, patient's parent(s) or legally authorized guardian(s) must have voluntarily signed an institutional review board (irb)/independent ethics committee (iec) approved informed consent form after all relevant aspects of the study have been explained and discussed. consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, as relevant, must be obtained. group 2: retrospective data inclusion criteria: retrospective patient group patients will be enrolled in hos and not study shp-ela-401; however, their growth data may be included in the analysis for study shp-ela-401 if the following data inclusion criteria are met. 1. the patient is male. 2. the patient is enrolled in hos. 3. the patient was \<6 years of age at the start of elaprase treatment. 4. the patient received elaprase weekly treatment for at least 5 years. 5. the patient had a height assessment and a weight assessment documented within 3 months before or after elaprase treatment start. 6. the patient has had annual height and weight assessments from start of elaprase through age 10 years. 7. the patient, patient's parent(s), or legally authorized guardian(s) agree(s) to data collection. 8. the patient, patient's parent(s), or legally authorized guardian(s) must have signed an irb/iec-approved informed consent form after all relevant aspects of the hos study have been explained and discussed. consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, as relevant, must be obtained. exclusion criteria: * group 1: prospective patient group 1. the patient has received treatment with any investigational drug or device within the 30 days prior to study entry. 2. the patient has received or is receiving treatment with idursulfase-it. 3. the patient has received growth hormones, a cord blood infusion, or a bone marrow transplant at any time. 4. the patient has received blood product transfusions within 90 days prior to screening. 5. the patient is unable to comply with the protocol as determined by the investigator. group 2: retrospective data exclusion criteria: hos patients that meet the following criteria are not eligible to be included into the study shp-ela-401 primary growth analysis: 1. patient was treated with growth hormone or other medications or interventions intended to promote growth in the time period covered by the analysis.